SBI Mutual Fund increased its stake in Gland Pharma from 3.29% to 3.32%, buying 71,408 shares for ₹17.48 crore at ₹2449 apiece.
A vertically integrated injectable-focused pharmaceutical company, Gland Pharma develops, manufactures, and markets complex injectables for global markets across the United States, Europe, Canada, Australia, and India. Established in Hyderabad in 1978, the company operates on a business-to-business model and serves customers in over 60 countries worldwide. Known for its expertise in complex injectable formulations, it maintains a strong presence across the value chain. Gland Pharma is promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
India's largest AMC by total AUM, managing over Rs 11 lakh crore across equity, debt and hybrid schemes. Backed by State Bank of India, the country's largest bank, which gives it unmatched retail reach across every Indian state. With over 70 schemes and 50 million folios, SBI MF's positioning moves are tracked as a proxy for domestic institutional flows.
